Conceptos Categóricos

PREVALENCIA AUMENTADA DE SINDROME METABOLICA EM PACIENTES COM TRANSTORNOS MENTAIS

PREVALENCIA AUMENTADA DE SINDROME METABOLICA EM PACIENTES COM TRANSTORNOS MENTAIS

(especial para SIIC © Derechos reservados)
Os estudos encontrados nessa revisão indicam prevalência aumentada de síndrome metabólica em pacientes com transtornos mentais graves. Em se tratando de pacientes com esquizofrenia ou transtorno esquizoafetivo, os estudos são concordantes em apontar para uma prevalência elevada de SM. Um único estudo encontrado constatou prevalência discretamente aumentada de síndrome metabólica em pacientes com transtorno bipolar.
Autor:
Paulo José Ribeiro Teixeira
Columnista Experto de SIIC

Institución:
Instituto de Previdência dos Servidores do Estaod de Minas Gerais (IPSEMG)


Artículos publicados por Paulo José Ribeiro Teixeira
Coautor
Paulo José Ribeiro Teixeira* 
Médico, Instituto de Previdência dos Servidores do Estaod de Minas Gerais (IPSEMG), Minas Gerais, Brasil*
Aprobación
6 de Junio, 2007
Primera edición
19 de Junio, 2008
Segunda edición, ampliada y corregida
23 de Febrero, 2009

Artículo completo

(castellano)
Extensión:  +/-3.54 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Endocrinología y Metabolismo, Salud Mental
Relacionadas: Atención Primaria, Cardiología, Epidemiología, Farmacología, Medicina Interna



Comprar este artículo
Extensión: 3.54 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Paulo José Ribeiro Teixeira, Instituto de Previdência dos Servidores do Estaod de Minas Gerais (IPSEMG), 30112-000, Rua Fernandes Tourinho 470, sala 903, Minas Gerais, Brasil
Bibliografía del artículo
1. Reaven GM. Syndrome X: 6 years later. J Int Med 236(Suppl.736):13-22, 1994.

2. Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 162:1217-21, 2005.

3. Correll CU, Frederickson AM, Kane JA, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second generation antipsychotic drugs. J Clin Psychiatry 67:575-83, 2006.

4. Crabtree LH. Offsetting metabolic abnormalities and premature death in medicated patients. In: 157th annual meeting of the American Psychiatry Association New York. Abstract 545, 2004.

5. Basu R, Brar JS, Chengappa KNR, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord 6:314-8, 2004.

6. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of metabolic syndrome. Can J Psychiatry 49:753-60, 2004.

7. De Hert MA, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87-93, 2006.

8. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21:93-8, 2006.

9. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka, J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575-9, 2003.

10. Kato MM, Currier MB, Gómez CM, Hall L, González Blanco M. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 6:74-7, 2004.

11. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32, 2005.

12. Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, Wirshing D. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 12:5-10, 2006.

13- Pandina GJ, Greenspan A, Bossie C, Turkoz I, Morein J, Meyer JM. Metabolic syndrome in patients with schizophrenia. In: 157th annual meeting of the American Psychiatric Association, New York. Abstract 584, 2004.

14- Littrell KH, Petty RG, Ortega TR, Moore D, Ballard A, Clough R, et al. Insulin resistance and syndrome X among patients with schizophrenia. In: 156th annual meeting of the American Psychiatric Association, San Francisco. Abstract 550, 2003.

15. Saari KM, Sari ML, Villo KM, Isohanni MK, Järvelin MR, Laurén LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. J Clin Psychiatry 66:559-63, 2005.

16. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 7:424-30, 2005.

17. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 66:316-22, 2004.

18. Carnethon MR, Kinder LS, Fair JM, Randall SS, Fortmann SP. Symptons of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971-1992. Am J Epidemiol 158:416-23, 2003.

19. Everson-Rose SA, Meyer PM, Powell LH, Pandey D, Torréns JI, Kravitz HM, et al. Depressive symptons, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 27:2856-62, 2004.

20. Lawlor DA, Smith GD, Ebrahim S. Association of insulin resistance with depression: cross sectional findings from the British women's heart and health study. BMJ 327:1383-4, 2003.

21. Lawlor DA, Ben-Shlomo Y, Ebrahim S, Smith GD, Stansfeld SA, Yarnell JWG, Gallacher JEJ. Insulin resistance and depressive symptons in middle aged men: findings from the Caerphilly prospective cohort study. BMJ 330:705-6, 2005.

22. Okamura F, Tashiro A, Utumi A, Towako I, Takatosi S, Tamura D, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 49:1255-60, 2000.

23. Timonen M, Laakso M, Jokelainen J, Rajala U, Meyer-Rochow VB, Keinänen-Kiukaanniemi S. Insulin resistance and depression: cross ectional study. BMJ 330:17-8, 2005.

24. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701, 1999.

25. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60:215-20, 1999.

26. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment - the metabolic syndrome. Life Sciences 71:239-57, 2002.

27. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 62:486-91, 2001.

28. Räikkönen K, Keltikangas-Järvinen L, Adlercreutz H, Hautanen A. Psychosocial stress and the insulin resistance syndrome. Metabolism 45:1533-8, 1996.

29. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry 184(Suppl.470):102S-5S, 2004.

30. Ramasubbu R. Insuline resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. Medical Hypothesis 59:537-51, 2002.

31. Hofman PL, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM, Cutfield WS. Premature birth and later insulin resistance. N Engl J Med 351:2179-86, 2004.

32. Holt RIG, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 21:515-23, 2004.

33. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 65:267-72, 2004.

34. Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sánchez JM, Navarro MA, San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335-42, 2004.

Título español
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

  English title
  Abstract
  Key words
Full text
(exclusivo a suscriptores)


Autor 
Artículos
Correspondencia
Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
-->